Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ablation of Reentry-Vulnerable Zones Determined by Left Ventricular Activation From Multiple Directions: A Novel Approach for Ventricular Tachycardia Ablation: A Multicenter Study (PHYSIO-VT)

E. Anter, P. Neuzil, VY. Reddy, J. Petru, KM. Park, J. Sroubek, E. Leshem, PJ. Zimetbaum, AE. Buxton, AG. Kleber, C. Shen, AL. Wit,

. 2020 ; 13 (6) : e008625. [pub] 20200506

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, Research Support, N.I.H., Extramural

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028118

Grantová podpora
T32 HL007374 NHLBI NIH HHS - United States

BACKGROUND: The optimal method to identify the arrhythmogenic substrate of scar-related ventricular tachycardia (VT) is unknown. Sites of activation slowing during sinus rhythm (SR) often colocalize with the VT circuit. However, the utility and limitations of such approach for guiding ablation are unknown. METHODS: We conducted a multicenter study in patients with infarct-related VT. The left ventricular (LV) was mapped during activation from 3 directions: SR (or atrial pacing), right ventricular, and LV pacing at 600 ms. Ablation was applied selectively to the cumulative area of slow activation, defined as the sum of all regions with activation times of ≥40 ms per 10 mm. Hemodynamically tolerated VTs were mapped with activation or entrainment. The primary outcome was a composite of appropriate implanted cardioverter-defibrillator therapies and cardiovascular death. RESULTS: In 85 patients, the LV was mapped during activation from 2.4±0.6 directions. The direction of LV activation influenced the location and magnitude of activation slowing. The spatial overlap of activation slowing between SR and right ventricular pacing was 84.2±7.1%, between SR and LV pacing was 61.4±8.8%, and between right ventricular and LV pacing was 71.3±9.6% (P<0.05 between all comparisons). Mapping during SR identified only 66.2±8.2% of the entire area of activation slowing and 58% critical isthmus sites. Activation from other directions by right ventricular and LV stimulation unmasked an additional 33% of slowly conducting zones and 25% critical isthmus sites. The area of maximal activation slowing often corresponded to the site where the wavefront first interacted with the infarct. During a follow-up period of 3.6 years, the primary end point occurred in 14 out of 85 (16.5%) patients. CONCLUSIONS: The spatial distribution of activation slowing is dependent on the direction of LV activation with the area of maximal slowing corresponding to the site where the wavefront first interacts with the infarct. This data may have implications for VT substrate mapping strategies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028118
003      
CZ-PrNML
005      
20210114153024.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/CIRCEP.120.008625 $2 doi
035    __
$a (PubMed)32372657
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Anter, Elad $u Cardiac Electrophysiology Section, Department of Cardiovascular Medicine, Cleveland Clinic, OH (E.A.).
245    10
$a Ablation of Reentry-Vulnerable Zones Determined by Left Ventricular Activation From Multiple Directions: A Novel Approach for Ventricular Tachycardia Ablation: A Multicenter Study (PHYSIO-VT) / $c E. Anter, P. Neuzil, VY. Reddy, J. Petru, KM. Park, J. Sroubek, E. Leshem, PJ. Zimetbaum, AE. Buxton, AG. Kleber, C. Shen, AL. Wit,
520    9_
$a BACKGROUND: The optimal method to identify the arrhythmogenic substrate of scar-related ventricular tachycardia (VT) is unknown. Sites of activation slowing during sinus rhythm (SR) often colocalize with the VT circuit. However, the utility and limitations of such approach for guiding ablation are unknown. METHODS: We conducted a multicenter study in patients with infarct-related VT. The left ventricular (LV) was mapped during activation from 3 directions: SR (or atrial pacing), right ventricular, and LV pacing at 600 ms. Ablation was applied selectively to the cumulative area of slow activation, defined as the sum of all regions with activation times of ≥40 ms per 10 mm. Hemodynamically tolerated VTs were mapped with activation or entrainment. The primary outcome was a composite of appropriate implanted cardioverter-defibrillator therapies and cardiovascular death. RESULTS: In 85 patients, the LV was mapped during activation from 2.4±0.6 directions. The direction of LV activation influenced the location and magnitude of activation slowing. The spatial overlap of activation slowing between SR and right ventricular pacing was 84.2±7.1%, between SR and LV pacing was 61.4±8.8%, and between right ventricular and LV pacing was 71.3±9.6% (P<0.05 between all comparisons). Mapping during SR identified only 66.2±8.2% of the entire area of activation slowing and 58% critical isthmus sites. Activation from other directions by right ventricular and LV stimulation unmasked an additional 33% of slowly conducting zones and 25% critical isthmus sites. The area of maximal activation slowing often corresponded to the site where the wavefront first interacted with the infarct. During a follow-up period of 3.6 years, the primary end point occurred in 14 out of 85 (16.5%) patients. CONCLUSIONS: The spatial distribution of activation slowing is dependent on the direction of LV activation with the area of maximal slowing corresponding to the site where the wavefront first interacts with the infarct. This data may have implications for VT substrate mapping strategies.
650    _2
$a akční potenciály $7 D000200
650    _2
$a senioři $7 D000368
650    12
$a katetrizační ablace $x škodlivé účinky $x mortalita $7 D017115
650    _2
$a elektrofyziologické techniky kardiologické $7 D022062
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční frekvence $7 D006339
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a rizikové faktory $7 D012307
650    _2
$a komorová tachykardie $x diagnóza $x mortalita $x patofyziologie $x chirurgie $7 D017180
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Evropa $7 D005060
651    _2
$a Korejská republika $7 D056910
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Neuzil, Petr $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N., V.Y.R., J.P.).
700    1_
$a Reddy, Vivek Y $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N., V.Y.R., J.P.). Helmsley Electrophysiology Center, Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY (V.Y.R.).
700    1_
$a Petru, Jan $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic (P.N., V.Y.R., J.P.).
700    1_
$a Park, Kyoung-Min $u Division of Cardiology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan university, Seoul, Republic of Korea (K.-M.P.).
700    1_
$a Sroubek, Jakub $u Harvard-Thorndike Electrophysiology Institute, Cardiovascular Division, Department of Medicine (J.S., E.L., P.J.Z., A.E.B., A.G.K.), Beth Israel Deaconess Medical Center, Harvard Medical School.
700    1_
$a Leshem, Eran $u Harvard-Thorndike Electrophysiology Institute, Cardiovascular Division, Department of Medicine (J.S., E.L., P.J.Z., A.E.B., A.G.K.), Beth Israel Deaconess Medical Center, Harvard Medical School.
700    1_
$a Zimetbaum, Peter J $u Harvard-Thorndike Electrophysiology Institute, Cardiovascular Division, Department of Medicine (J.S., E.L., P.J.Z., A.E.B., A.G.K.), Beth Israel Deaconess Medical Center, Harvard Medical School.
700    1_
$a Buxton, Alfred E $u Harvard-Thorndike Electrophysiology Institute, Cardiovascular Division, Department of Medicine (J.S., E.L., P.J.Z., A.E.B., A.G.K.), Beth Israel Deaconess Medical Center, Harvard Medical School.
700    1_
$a Kleber, Andre G $u Harvard-Thorndike Electrophysiology Institute, Cardiovascular Division, Department of Medicine (J.S., E.L., P.J.Z., A.E.B., A.G.K.), Beth Israel Deaconess Medical Center, Harvard Medical School.
700    1_
$a Shen, Changyu $u Richard A. and Susan F. Smith Center for Cardiovascular Outcomes Research, Division of Cardiovascular Medicine (C.S.), Beth Israel Deaconess Medical Center, Harvard Medical School.
700    1_
$a Wit, Andrew L $u Department of Pharmacology, College of Physicians and Surgeons of Columbia University, New York, NY (A.L.W.).
773    0_
$w MED00159578 $t Circulation. Arrhythmia and electrophysiology $x 1941-3084 $g Roč. 13, č. 6 (2020), s. e008625
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32372657 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114153021 $b ABA008
999    __
$a ok $b bmc $g 1608453 $s 1119298
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 13 $c 6 $d e008625 $e 20200506 $i 1941-3084 $m Circulation. Arrhythmia and electrophysiology $n Circ Arrhythm Electrophysiol $x MED00159578
GRA    __
$a T32 HL007374 $p NHLBI NIH HHS $2 United States
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace